


WHO GUIDELINES
on **MANAGEMENT**
of ***TAENIA SOLIUM***
NEUROCYSTICERCOSIS



World Health
Organization



WHO GUIDELINES
on **MANAGEMENT**
of ***TAENIA SOLIUM***
NEUROCYSTICERCOSIS



World Health
Organization

WHO guidelines on management of *Taenia solium* neurocysticercosis

ISBN 978-92-4-003223-1 (electronic version)

ISBN 978-92-4-003224-8 (print version)

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. WHO guidelines on management of *Taenia solium* neurocysticercosis. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

CONTENTS

Acknowledgements.....	v
Abbreviations and acronyms	vi
Executive summary	vii
INTRODUCTION	1
METHODS.....	4
Main points	4
Contributors	4
Guideline development	5
RECOMMENDATION FOR DIAGNOSIS OF <i>T. SOLIUM</i> PARENCHYMAL NEUROCYSTICERCOSIS	13
RECOMMENDATION FOR TREATMENT OF <i>T. SOLIUM</i> PARENCHYMAL NEUROCYSTICERCOSIS	14
Treatment of neurocysticercosis with anthelmintics and anti-inflammatory agents	14
Treatment of neurocysticercosis and epilepsy with antiepileptic drugs	16
Treatment of neurocysticercosis in immunocompromised patients	17
RESEARCH PRIORITIES	18
Diagnosis of parenchymal neurocysticercosis	18
Treatment of parenchymal neurocysticercosis.....	18
THE GUIDELINES	20
Main points.....	20
Dissemination	20
Implementation	20
Updating	20
References.....	21
ANNEX 1 – CONTRIBUTORS.....	25
ANNEX 2 – DECLARATIONS OF INTERESTS	27
ANNEX 3 – SYSTEMATIC REVIEW SEARCH STRATEGY	29
ANNEX 4 – EVIDENCE PROFILES	31
Evidence profile: Question 1	31
Evidence profile: Questions 2 and 3	40
Evidence profile: Questions 4 and 5	55
Evidence profile: Question 6	67
Evidence profile: Question 7	75
Evidence profile: Questions 8 and 9	80

ACKNOWLEDGEMENTS

The departments of Control of Neglected Tropical Diseases and Mental Health and Substance Use of the World Health Organization (WHO) gratefully acknowledge the contributions of many individuals and organizations to the development of these guidelines.

The members of the WHO Steering Group for guideline development were Bernadette Abela-Ridder, Veterinary Public Health, Vector Control and Environment; Daniel Dagne, Prevention, Treatment and Care; Tarun Dua, Brain Health; Amadou Garba Djirmay, Prevention, Treatment and Care; Nicoline Schiess, Brain Health; Anthony Solomon, Neglected Tropical Diseases; Elkhani Gasimov, Malaria, Neglected Tropical Diseases and other Vector-borne Diseases, WHO Regional Office for Europe; and Ruben Santiago Nicholls, Neglected Infectious Diseases, WHO Regional Office for the Americas.

The members of the Guideline Development Group (GDG) were Peter Chiodini, Hospital for Tropical Diseases, London School of Hygiene & Tropical Medicine, Public Health England Malaria Reference Laboratory and National Parasitology Reference Laboratory; Christina Coyle, who served as Chair of the GDG, Albert Einstein College of Medicine, New York City (NY), United States of America; Oscar Del Brutto, Kennedy Hospital-Clinic, Guayaquil, Ecuador; Sarah Gabriel, Ghent University, Belgium; Hector Garcia, National Institute of Neurological Sciences, Lima, Peru; Mamoun Homeida, University of Medical Sciences & Technology, Khartoum, Sudan; Virak Khieu, Ministry of Health, Cambodia; Theodore Nash, Laboratory of Parasitic Diseases, Bethesda (MD), United States of America; Bernard Ngowi, National Institute for Medical Research, Dar es Salaam, United Republic of Tanzania; Vedantam Rajshekhar, Christian Medical College, Vellore, India; Gagandeep Singh, Dayanand Medical College, Ludhiana, India and Institute of Neurology, London, United Kingdom; Clinton White, University of Texas, Galveston (TX), United States of America; and Xiao Nong Zhou, Chinese Center for Disease Control and Prevention, Shanghai, China. Hélène Carabin, University of Montreal, was the GDG methodologist.

Special thanks to members of the systematic review team: Annette Abraham, Center for Global Health, Technical University of Munich, Germany; and Javier Bustos, Instituto Nacional de Ciencias Neurológicas, Lima, Peru, with oversight by Hector Garcia, National Institute of Neurological Sciences, Lima, Peru, and Andrea Sylvia Winkler, Center for Global Health, Technical University of Munich, Germany and Centre for Global Health, University of Oslo, Norway.

WHO would also like to thank the following WHO regional advisors for their contributions: Elkhani Gasimov, Malaria, Neglected Tropical Diseases and other Vector-borne Diseases, Regional Office for Europe; Ruben Santiago Nicholls, Neglected Infectious Diseases, Regional Office for the Americas; Dr Alexandre Tiendrebeogo, Communicable and Noncommunicable Diseases, Regional Office for Africa; Dr Supriya Warusavithana, Neglected Tropical Diseases, Regional Office for the Eastern Mediterranean; Dr Mohamed Jamsheed, Vector-borne and Neglected Tropical Diseases Control, Regional Office for South-East Asia; and Dr Aya Yajima, Malaria and Neglected Tropical Diseases, Regional Office for the Western Pacific.

Many thanks to members of the external review group: Paul T. Cantey, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta (GA), United States of America; Pierre Dorny, Institute of Tropical Medicine, Antwerp, Belgium; Agnes Fleury, Instituto Nacional de Neurología y Neurocirugía, México City, Mexico; Marco Tulio Medina, National Autonomous University of Honduras; Sylvia Ramiandrasoa, Ministry of Public Health, Antananarivo, Madagascar; Veronika Schmidt, Center for Global Health, Technical University Munich, Germany; and Osvaldo Takayanagui, University of São Paulo, Brazil.

WHO appreciates the feedback of many international stakeholders during guideline development, including the Cysticercosis and Taeniosis Network of Sub-Saharan Africa (CYSTINET-Africa) (1) – a resource base for the guideline development process and implementation.

Funding was provided for this guideline by the Bill & Melinda Gates Foundation, Seattle (WA), United States of America. The views of the funding body have not influenced the content of this guideline.

ABBREVIATIONS and ACRONYMS

AED	antiepileptic drug
ALB	albendazole
CI	confidence interval
CT	computerized tomography
DXM	dexamethasone
GDG	Guideline Development Group
GRADE	Grading of Recommendations Assessment, Development and Evaluation
LMIC	low- and middle-income countries
mhGAP	Mental Health Gap Action Programme
MRI	magnetic resonance imaging
PICO	population, intervention, comparator, outcome
PRED	prednisolone
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
PZQ	praziquantel
RCT	randomized controlled trial
RR	relative risk
SEL	single enhancing lesion
WHO	World Health Organization

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_23630

